Evidence map›Paper›PMID 38567951›Full record

ArticleJournal of virology2024

Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.

Nathalie Mantel, Fabienne Piras-Douce, Emilie Chautard, Ernesto Marcos-Lopez, Caroline L Bodinham, Antonio Cosma, Virginie Courtois, Nina Dhooge, Sylviane Gautheron, Stefan H E Kaufmann and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 4 countries.

Nathalie MantelResearch and Development, Sanofi, Marcy L'Etoile, France.ORCID 0000-0001-8984-3183
Fabienne Piras-DouceResearch and Development, Sanofi, Marcy L'Etoile, France.
Emilie ChautardResearch and Development, Sanofi, Marcy L'Etoile, France.
Ernesto Marcos-LopezUniversité Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.
Caroline L BodinhamSurrey Clinical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom.
Antonio CosmaUniversité Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.
Virginie CourtoisResearch and Development, Sanofi, Marcy L'Etoile, France.
Nina DhoogeUniversité Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.
Sylviane GautheronResearch and Development, Sanofi, Marcy L'Etoile, France.
Stefan H E KaufmannMax Planck Institute for Infection Biology, Berlin, Germany; Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Kathleen PizzoferroSurrey Clinical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom.
David J M LewisSurrey Clinical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom.
Frédéric MartinonUniversité Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.
Anke PagnonResearch and Development, Sanofi, Marcy L'Etoile, France.
Franck RaynalResearch and Development, Sanofi, Marcy L'Etoile, France.
Nathalie Dereuddre-BosquetUniversité Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.
Roger Le GrandUniversité Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay aux Roses, France.
Sanofi (France) · FRInserm · FRUniversity of Surrey · GBInstitute for Advanced Study · US

Funding

ANR ANR-10-EQPX-02-01ANR ANR-11-INBS-0008Innovative Medicines Initiative Joint Undertaking n.115308
6 · The paper itself

Abstract

The non-human primate (NHP) model (specifically rhesus and cynomolgus macaques) has facilitated our understanding of the pathogenic mechanisms of yellow fever (YF) disease and allowed the evaluation of the safety and efficacy of YF-17D vaccines. However, the accuracy of this model in mimicking vaccine-induced immunity in humans remains to be fully determined. We used a systems biology approach to compare hematological, biochemical, transcriptomic, and innate and antibody-mediated immune responses in cynomolgus macaques and human participants following YF-17D vaccination. Immune response progression in cynomolgus macaques followed a similar course as in adult humans but with a slightly earlier onset. Yellow fever virus neutralizing antibody responses occurred earlier in cynomolgus macaques [by Day 7[(D7)], but titers > 10 were reached in both species by D14 post-vaccination and were not significantly different by D28 [plaque reduction neutralization assay (PRNT)

Indexed as

Macaca fascicularisModels, AnimalYellow Fever VaccineAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansImmunity, InnateMaleSystems BiologyVaccinationYellow FeverYellow fever virusAntibodies, NeutralizingAntibodies, ViralYellow Fever Vaccinehumannon-human primatevaccineyellow fever

Identifiers

PMID38567951
PMCPMC11092345
OpenAlexW4393898813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.